261 related articles for article (PubMed ID: 32104382)
21. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation.
Changsan N; Chan HK; Separovic F; Srichana T
J Pharm Sci; 2009 Feb; 98(2):628-39. PubMed ID: 18484099
[TBL] [Abstract][Full Text] [Related]
22. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
AAPS PharmSciTech; 2004 Aug; 5(4):e65. PubMed ID: 15760062
[TBL] [Abstract][Full Text] [Related]
23. Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers.
Zhang T; Chen Y; Ge Y; Hu Y; Li M; Jin Y
Acta Pharm Sin B; 2018 May; 8(3):440-448. PubMed ID: 29881683
[TBL] [Abstract][Full Text] [Related]
24. Customizable resveratrol spray-dried micro-composites for inhalation as a promising contender for treatment of idiopathic pulmonary fibrosis.
Ahmed S; Mansour M; Ishak RAH; Mortada ND
Int J Pharm; 2023 Jul; 642():123117. PubMed ID: 37315636
[TBL] [Abstract][Full Text] [Related]
25. A triple combination 'nano' dry powder inhaler for tuberculosis: in vitro and in vivo pulmonary characterization.
Chogale MM; Dhoble SB; Patravale VB
Drug Deliv Transl Res; 2021 Aug; 11(4):1520-1531. PubMed ID: 34041715
[TBL] [Abstract][Full Text] [Related]
26. Predicting in vitro lung deposition behavior of combined dry powder inhaler via rheological properties.
Li J; Ma S; Sun Y; Song R; Cai B; Li H; Chen Y; Zhang X; Guan J; Mao S
Eur J Pharm Biopharm; 2022 Dec; 181():195-206. PubMed ID: 36400254
[TBL] [Abstract][Full Text] [Related]
27. Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization.
Joshi M; Misra A
Int J Pharm; 2001 Jul; 223(1-2):15-27. PubMed ID: 11451628
[TBL] [Abstract][Full Text] [Related]
28. Dry powder inhaler device influence on carrier particle performance.
Donovan MJ; Kim SH; Raman V; Smyth HD
J Pharm Sci; 2012 Mar; 101(3):1097-107. PubMed ID: 22095397
[TBL] [Abstract][Full Text] [Related]
29. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
30. Inhalable liposomal dry powder of gemcitabine-HCl: Formulation, in vitro characterization and in vivo studies.
Gandhi M; Pandya T; Gandhi R; Patel S; Mashru R; Misra A; Tandel H
Int J Pharm; 2015 Dec; 496(2):886-95. PubMed ID: 26453787
[TBL] [Abstract][Full Text] [Related]
31. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
Sommerfeld M; Cui Y; Schmalfuß S
Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
[TBL] [Abstract][Full Text] [Related]
32. Influence of physical properties of carrier on the performance of dry powder inhalers.
Peng T; Lin S; Niu B; Wang X; Huang Y; Zhang X; Li G; Pan X; Wu C
Acta Pharm Sin B; 2016 Jul; 6(4):308-18. PubMed ID: 27471671
[TBL] [Abstract][Full Text] [Related]
33. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
34. Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery.
Rattanupatam T; Srichana T
Drug Deliv; 2014 Sep; 21(6):397-405. PubMed ID: 24401124
[TBL] [Abstract][Full Text] [Related]
35. Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships.
Lim JG; Shah B; Rohatagi S; Bell A
Am J Ther; 2006; 13(1):32-42. PubMed ID: 16428920
[TBL] [Abstract][Full Text] [Related]
36. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma.
Reichel W; Dahl R; Ringdal N; Zetterstrom O; van den Elshout FJ; Laitinen LA
Int J Clin Pract; 2001 Mar; 55(2):100-6. PubMed ID: 11321849
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
38. Preparation and Characterization of a Dry Powder Inhaler Composed of PLGA Large Porous Particles Encapsulating Gentamicin Sulfate.
Shiehzadeh F; Tafaghodi M; Dehghani ML; Mashhoori F; Fazly Bazzaz BS; Imenshahidi M
Adv Pharm Bull; 2019 Jun; 9(2):255-261. PubMed ID: 31380251
[No Abstract] [Full Text] [Related]
39. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
40. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
Shaji J; Menon I
Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
